Astrazeneca

Astrazeneca

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

About Astrazeneca

Latest Astrazeneca Share price

LON: AZN Dividends

Historical Data

Latest Astrazeneca News

AstraZeneca

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive...
AstraZeneca

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer,...
AstraZeneca

FDA approves AstraZeneca’s Saphnelo Pen for self-administration in SLE

AstraZeneca’s Saphnelo has received US approval as a once-weekly autoinjector for adults with systemic lupus erythematosus, offering a self-administered alternative...
AstraZeneca

Third positive Phase III trial supports AstraZeneca’s tozorakimab in COPD

High-level data from the MIRANDA study showed AstraZeneca’s IL-33-targeting biologic tozorakimab significantly lowered annualised moderate-to-severe COPD exacerbations and was generally...
intravenous (IV) line

AstraZeneca reports positive Phase III EMERALD-3 results in unresectable liver cancer

In the Phase III EMERALD-3 trial, AstraZeneca’s Imfinzi- and Imjudo-based regimen plus lenvatinib and TACE significantly improved progression-free survival versus...
intravenous (IV) line

EU approves AstraZeneca’s Imfinzi with FLOT chemotherapy for early gastric cancer

AstraZeneca’s immunotherapy Imfinzi has been approved in the EU as part of a perioperative regimen with FLOT chemotherapy for resectable...
AstraZeneca

AstraZeneca secures US Approval for fixed-duration Calquence regimen in CLL

AstraZeneca’s Calquence plus venetoclax has been approved in the US as the first all-oral, 14-month treatment option for adults with...
AstraZeneca

AstraZeneca Q4 and FY 2025: Strong sales growth and pipeline momentum

Excerpt In FY 2025, AstraZeneca achieved 9% reported revenue growth and a 45% increase in reported EPS, reflecting strong commercial...
AstraZeneca

AstraZeneca Plc begins trading on the New York Stock Exchange

AstraZeneca has started trading its ordinary shares on the NYSE for the first time, aligning its listings across New York,...
AstraZeneca

AstraZeneca signs $1.2bn obesity drug collaboration with CSPC

Under a new agreement with CSPC Pharmaceuticals, AstraZeneca will advance eight programmes targeting obesity and weight-related conditions, initially progressing four...
AstraZeneca

AstraZeneca to move Nasdaq listing to NYSE

AstraZeneca PLC has notified of the voluntary withdrawal of its American Depositary Shares and certain debt securities from The Nasdaq...
AstraZeneca

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for...

Share this page

Twitter
LinkedIn
Facebook
Email
WhatsApp

Data policy – All information should be used for indicative purposes only. You should independently check data before making any investment decision and or seek professional advice. DirectorsTalk cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.